- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Royal Bank Of Canada Raises Biogen Price Target
Analysts increase price target on biotech company's stock to $233.00
Published on Feb. 9, 2026
Got story updates? Submit your updates here. ›
Royal Bank Of Canada has raised its price target on Biogen (NASDAQ:BIIB) from $217.00 to $233.00 and maintained an "outperform" rating on the biotechnology company's stock. The new price target represents a potential upside of 15.82% from Biogen's previous closing price.
Why it matters
Biogen is a major player in the biotechnology industry, particularly in the development of treatments for neurological and neurodegenerative diseases. The increased price target from a prominent analyst firm suggests growing confidence in the company's future performance and product pipeline.
The details
In a research note, Royal Bank Of Canada analysts cited Biogen's strong product portfolio and pipeline as reasons for the increased price target. The company's shares have traded in the range of $110.04 to $202.41 over the past 52 weeks.
- Royal Bank Of Canada issued the updated price target and rating on Monday, February 9, 2026.
The players
Biogen
A multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases.
Royal Bank Of Canada
A prominent financial services company that provides various banking products and services.
What they’re saying
“We must not let individuals continue to damage private property in San Francisco.”
— Robert Jenkins, San Francisco resident (San Francisco Chronicle)
The takeaway
The increased price target from Royal Bank Of Canada reflects growing confidence in Biogen's ability to deliver value for investors through its innovative product pipeline and market leadership in key therapeutic areas.
